In people with recurrent aphthous stomatitis, Atorvastatin mucoadhesive tablets effectively relieve pain, discomfort, and also cause healing and size reduction of aphthous lesions.

This study sought to assess the effectiveness of Atorvastatin tablets as a topical therapy in minimizing the duration and symptoms of stomatitis.

Participants were divided into two groups: Atorvastatin group and Placebo group. The recruited subjects received three mucoadhesive tablets daily (night, noon, morning). Evaluations were conducted on days 0 (baseline), 3, 5, and 7 to measure inflammatory halo diameter. With the aid of Visual Analog Scale (VAS), pain intensity was examined for up to 7 days after each meal. Data analysis was done utilizing SPSS 24 software.

At baseline, there was no profound difference in halo diameter between the two groups in this randomized double-blinded clinical trial. But, on the 3rd, 5th, and 7th days of the study, a notable difference emerged. The Atorvastatin group exhibited a reduction in lesion size and shorter healing time when compared to the placebo group. Furthermore, the Atorvastatin group experienced a considerable reduction in pain intensity (VAS) except on the first, second, and seventh days of the study, as shown in Figure 1:

Owing to their anti-inflammatory and wound-healing properties, Atorvastatin mucoadhesive tablets effectively alleviate pain, decrease lesion size, and accelerate healing in people battling with minor recurrent aphthous stomatitis. Therefore, the use of these tablets should be considered as a viable therapeutic choice.